{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:23:13Z","timestamp":1790659393716,"version":"4.1.0"},"reference-count":50,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:00:00Z","timestamp":1736208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Science and Higher Education of the Russian Federation for RCMG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the CFTR gene. Currently, CFTR modulators are the most effective treatment for CF; however, they may not be suitable for all patients. A representative and convenient in vitro model is needed to screen therapeutic agents under development. This study, on the most common mutation, F508del, investigates the efficacy of human induced pluripotent stem cell-derived lung organoids (hiLOs) from NKX2.1+ lung progenitors and airway basal cells (hiBCs) as a 3D model for CFTR modulator response assessment by a forskolin-induced swelling assay. Weak swelling was observed for hiLOs from NKX2.1+ lung progenitors and hiBCs in response to modulators VX-770\/VX-809 and VX-770\/VX-661, whereas the VX-770\/VX-661\/VX-445 combination resulted in the highest swelling response, indicating superior CFTR function restoration. The ROC analysis of the FIS assay results revealed an optimal cutoff of 1.21, with 65.9% sensitivity and 71.8% specificity, and the predictive accuracy of the model was 76.4%. In addition, this study compared the response of hiLOs with the clinical response of patients to therapy and showed similar drug response dynamics. Thus, hiLOs can effectively model the CF pathology and predict patients\u2019 specific response to modulators.<\/jats:p>","DOI":"10.3390\/ijms26020437","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T03:38:41Z","timestamp":1736221121000},"page":"437","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Human Induced Lung Organoids: A Promising Tool for Cystic Fibrosis Drug Screening"],"prefix":"10.3390","volume":"26","author":[{"given":"Anna","family":"Demchenko","sequence":"first","affiliation":[{"name":"Laboratory of Genome Editing, Research Centre for Medical Genetics, Moskvorechye, 1, 115522 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3097-344X","authenticated-orcid":false,"given":"Maxim","family":"Balyasin","sequence":"additional","affiliation":[{"name":"Scientific and Educational Resource Center, Peoples\u2019 Friendship University of Russia, Miklukho-Maklaya, 6, 117198 Moscow, Russia"},{"name":"Department of Cell Technology, Endocrinology Research Center, Dm. Ulyanova Str., 11, 117292 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Nazarova","sequence":"additional","affiliation":[{"name":"Laboratory of Genome Editing, Research Centre for Medical Genetics, Moskvorechye, 1, 115522 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Grigorieva","sequence":"additional","affiliation":[{"name":"Laboratory of Genome Editing, Research Centre for Medical Genetics, Moskvorechye, 1, 115522 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Panchuk","sequence":"additional","affiliation":[{"name":"Laboratory of Genome Editing, Research Centre for Medical Genetics, Moskvorechye, 1, 115522 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Kondrateva","sequence":"additional","affiliation":[{"name":"Laboratory of Genome Editing, Research Centre for Medical Genetics, Moskvorechye, 1, 115522 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vyacheslav","family":"Tabakov","sequence":"additional","affiliation":[{"name":"Moscow Branch of the Biobank \u201cAll-Russian Collection of Biological Samples of Hereditary Diseases\u201d, Research Centre for Medical Genetics, Moskvorechye, 1, 115522 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4905-1303","authenticated-orcid":false,"given":"Olga","family":"Schagina","sequence":"additional","affiliation":[{"name":"DNA-Diagnostics Laboratory, Research Centre for Medical Genetics, Moskvorechye, 1, 115522 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5356-9415","authenticated-orcid":false,"given":"Elena","family":"Amelina","sequence":"additional","affiliation":[{"name":"Laboratory of Cystic Fibrosis, Research Institute of Pulmonology, 11th Parkovaya Str., 32\/4, 105077 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Smirnikhina","sequence":"additional","affiliation":[{"name":"Laboratory of Genome Editing, Research Centre for Medical Genetics, Moskvorechye, 1, 115522 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/apa.15155","article-title":"Cystic fibrosis in the year 2020: A disease with a new face","volume":"109","year":"2020","journal-title":"Acta Paediatr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"BSR20212006","DOI":"10.1042\/BSR20212006","article-title":"Molecular mechanisms of cystic fibrosis-how mutations lead to misfunction and guide therapy","volume":"42","author":"Farinha","year":"2022","journal-title":"Biosci. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"690","DOI":"10.4081\/mrm.2020.690","article-title":"Novel therapeutic approaches for the management of cystic fibrosis","volume":"15","author":"Jaques","year":"2020","journal-title":"Multidiscip. Respir. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Fajac, I., and Sermet, I. (2021). Therapeutic approaches for patients with cystic fibrosis not eligible for current CFTR modulators. Cells, 10.","DOI":"10.3390\/cells10102793"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jcf.2013.06.008","article-title":"Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function","volume":"13","author":"Yu","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/j.jcf.2021.04.001","article-title":"Rapid cystic fibrosis lung-function decline and in-vitro CFTR modulation","volume":"20","author":"Gecili","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"344ra84","DOI":"10.1126\/scitranslmed.aad8278","article-title":"Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis","volume":"8","author":"Dekkers","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4187\/respcare.06697","article-title":"Cystic fibrosis lung disease: An overview","volume":"65","author":"Turcios","year":"2019","journal-title":"Respir. Care"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Malik, N., and Rao, M.S. (2013). A review of the methods for human iPSC derivation. Pluripotent Stem Cells: Methods and Protocols, Humana Press.","DOI":"10.1007\/978-1-62703-348-0_3"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12929-024-01035-4","article-title":"Exploiting urine-derived induced pluripotent stem cells for advancing precision medicine in cell therapy, disease modeling, and drug testing","volume":"31","author":"Yin","year":"2024","journal-title":"J. Biomed. Sci."},{"key":"ref_11","first-page":"55159","article-title":"Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients","volume":"120","author":"Boj","year":"2017","journal-title":"J. Vis. Exp."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/nm.3201","article-title":"A functional CFTR assay using primary cystic fibrosis intestinal organoids","volume":"19","author":"Dekkers","year":"2013","journal-title":"Nat. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3390\/jor1040022","article-title":"Three-Dimensional Airway Spheroids and Organoids for Cystic Fibrosis Research","volume":"1","author":"Laselva","year":"2021","journal-title":"J. Respir."},{"key":"ref_14","unstructured":"Said, H.M. (2018). Chapter 58\u2014Ion Channels of the Gastrointestinal Epithelial Cells. Physiology of the Gastrointestinal Tract, Academic Press. [6th ed.]."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jcf.2018.02.007","article-title":"Comparison of ex vivo and in vitro intestinal cystic fibrosis models to measure CFTR-dependent ion channel activity","volume":"17","author":"Kruisselbrink","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jcf.2018.05.004","article-title":"CFTR modulator theratyping: Current status, gaps and future directions","volume":"18","author":"Clancy","year":"2019","journal-title":"J. Cyst. Fibros."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Liu, Z., Anderson, J.D., Deng, L., Mackay, S., Bailey, J., Kersh, L., Rowe, S.M., and Guimbellot, J.S. (2020). Human Nasal Epithelial Organoids for Therapeutic Development in Cystic Fibrosis. Genes, 11.","DOI":"10.3390\/genes11060603"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e100300","DOI":"10.15252\/embj.2018100300","article-title":"Long-term expanding human airway organoids for disease modeling","volume":"38","author":"Sachs","year":"2019","journal-title":"EMBO J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2100908","DOI":"10.1183\/13993003.00908-2021","article-title":"Theratyping cystic fibrosis in vitro in ALI culture and organoid models generated from patient-derived nasal epithelial conditionally reprogrammed stem cells","volume":"58","author":"Sette","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1038\/s41467-022-31854-8","article-title":"A multimodal iPSC platform for cystic fibrosis drug testing","volume":"13","author":"Berical","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1242\/dev.118570","article-title":"Modeling mouse and human development using organoid cultures","volume":"142","author":"Huch","year":"2015","journal-title":"Development"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Aslam, A.A., Sinha, I.P., and Southern, K.W. (2023). Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis. Cochrane Database Syst. Rev., 3.","DOI":"10.1002\/14651858.CD012040.pub3"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Demchenko, A., Kondrateva, E., Tabakov, V., Efremova, A., Salikhova, D., Bukharova, T., Goldshtein, D., Balyasin, M., Bulatenko, N., and Amelina, E. (2023). Airway and Lung Organoids from Human-Induced Pluripotent Stem Cells Can Be Used to Assess CFTR Conductance. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076293"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.stem.2020.09.017","article-title":"Derivation of airway basal stem cells from human pluripotent stem Cells","volume":"28","author":"Hawkins","year":"2020","journal-title":"Cell Stem Cell"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1336392","DOI":"10.3389\/fcell.2024.1336392","article-title":"Airway basal cells from human-induced pluripotent stem cells: A new frontier in cystic fibrosis research","volume":"12","author":"Demchenko","year":"2024","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1902426","DOI":"10.1183\/13993003.02426-2019","article-title":"Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis","volume":"57","author":"Ramalho","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.stem.2017.03.001","article-title":"Efficient Derivation of Functional Human Airway Epithelium from Pluripotent Stem Cells via Temporal Regulation of Wnt Signaling","volume":"20","author":"McCauley","year":"2017","journal-title":"Cell Stem Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.3389\/fphar.2018.01429","article-title":"Human Primary Epithelial Cell Models: Promising Tools in the Era of Cystic Fibrosis Personalized Medicine","volume":"9","author":"Awatade","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Kondratyeva, E., Efremova, A., Melyanovskaya, Y., Voronkova, A., Polyakov, A., Bulatenko, N., Adyan, T., Sherman, V., Kovalskaia, V., and Petrova, N. (2022). Evaluation of the complex p.[Leu467Phe; Phe508del] CFTR allele in the intestinal organoids model: Implications for therapy. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231810377"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Sondo, E., Cresta, F., Pastorino, C., Tomati, V., Capurro, V., Pesce, E., Lena, M., Iacomino, M., Baffico, A.M., and Coviello, D. (2022). The L467F-F508del complex allele hampers pharmacological rescue of mutant CFTR by elexacaftor\/tezacaftor\/ivacaftor in cystic fibrosis patients: The value of the ex vivo nasal epithelial model to address nonresponders to CFTR-modulating drugs. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063175"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4097\/kja.21209","article-title":"Receiver operating characteristic curve: Overview and practical use for clinicians","volume":"75","author":"Nahm","year":"2022","journal-title":"Korean J. Anesthesiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1802379","DOI":"10.1183\/13993003.02379-2018","article-title":"Intestinal organoids to model cystic fibrosis","volume":"54","author":"Beekman","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"12771","DOI":"10.1073\/pnas.0906850106","article-title":"Basal cells as stem cells of the mouse trachea and human airway epithelium","volume":"106","author":"Rock","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/stem.3422","article-title":"SARS-CoV-2 infects an upper airway model derived from induced pluripotent stem cells","volume":"39","author":"Djidrovski","year":"2021","journal-title":"Stem Cells"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMoa1709847","article-title":"Tezacaftor\u2013ivacaftor in residual-function heterozygotes with cystic fibrosis","volume":"377","author":"Rowe","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor\u2013Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_37","first-page":"276","article-title":"The effectiveness and value of novel treatments for cystic fibrosis","volume":"27","author":"Tice","year":"2021","journal-title":"J. Manag. Care Sp\u00e9c. Pharm."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.celrep.2019.01.068","article-title":"Rectal organoids enable personalized treatment of cystic fibrosis","volume":"26","author":"Berkers","year":"2019","journal-title":"Cell Rep."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"265","DOI":"10.17816\/gc624124","article-title":"Personalized assessment of the effectiveness of targeted drugs for the treatment of cystic fibrosis in a patient with c.264_268delATATT and c.3139+1G>C rare variants of the CFTR gene","volume":"19","author":"Efremova","year":"2024","journal-title":"Genes Cells"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jcf.2024.04.014","article-title":"Repeatability and reproducibility of the Forskolin-induced swelling (FIS) assay on intestinal organoids from people with Cystic Fibrosis","volume":"23","author":"Bierlaagh","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Bacalhau, M., Camargo, M., and Lopes-Pacheco, M. (2024). Laboratory tools to predict CFTR modulator therapy effectiveness and to monitor disease severity in cystic fibrosis. J. Pers. Med., 14.","DOI":"10.3390\/jpm14010093"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"w20496","DOI":"10.4414\/smw.2021.20496","article-title":"Diagnostic tools and CFTR functional assays in cystic fibrosis: Utility and availability in Switzerland","volume":"151","author":"Elviro","year":"2021","journal-title":"Swiss Med. Wkly."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2100508","DOI":"10.1183\/13993003.00508-2021","article-title":"Forskolin-induced organoid swelling is associated with long-term cystic fibrosis disease progression","volume":"60","author":"Muilwijk","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e202101320","DOI":"10.26508\/lsa.202101320","article-title":"Measuring cystic fibrosis drug responses in organoids derived from 2D differentiated nasal epithelia","volume":"5","author":"Amatngalim","year":"2022","journal-title":"Life Sci. Alliance"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"102232","DOI":"10.1016\/j.scr.2021.102232","article-title":"Generation of two induced pluripotent stem cell lines (RCMGi004-A and -B) from human skin fibroblasts of a cystic fibrosis patient with compound heterozygous F508del\/W1282X mutations in CFTR gene","volume":"52","author":"Kondrateva","year":"2021","journal-title":"Stem Cell Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"101933","DOI":"10.1016\/j.scr.2020.101933","article-title":"Generation of induced pluripotent stem cell line (RCMGi001-A) from human skin fibroblasts of a cystic fibrosis patient with p.F508del mutation","volume":"48","author":"Kondrateva","year":"2020","journal-title":"Stem Cell Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"102896","DOI":"10.1016\/j.scr.2022.102896","article-title":"Generation of two induced pluripotent stem cell lines (RCMGi005-A\/B) from human skin fibroblasts of a cystic fibrosis patient with homozygous F508del mutation in CFTR gene","volume":"64","author":"Panchuk","year":"2022","journal-title":"Stem Cell Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"102251","DOI":"10.1016\/j.scr.2021.102251","article-title":"Derivation of iPSC line (RCMGi002-A) from dermal fibroblasts of a cystic fibrosis female patient with homozygous F508del mutation","volume":"53","author":"Kondrateva","year":"2021","journal-title":"Stem Cell Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"R100","DOI":"10.1186\/gb-2006-7-10-r100","article-title":"CellProfiler: Image analysis software for identifying and quantifying cell phenotypes","volume":"7","author":"Carpenter","year":"2006","journal-title":"Genome Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/s41592-019-0582-9","article-title":"Ilastik: Interactive machine learning for (bio) image analysis","volume":"16","author":"Berg","year":"2019","journal-title":"Nat. Methods"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/2\/437\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:23:59Z","timestamp":1759919039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/2\/437"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,7]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["ijms26020437"],"URL":"https:\/\/doi.org\/10.3390\/ijms26020437","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,7]]}}}